Foundation For Angelman Syndrome Therapeutics Australia Limited
Board Interlocks (1 shared directors)
Giving Philosophy
The foundation believes in the power of research and community support as key drivers for change, focusing on enabling and advocating for better therapeutic options for Angelman Syndrome. They emphasize collaboration with research institutions and health services to achieve meaningful outcomes.
Tips for Applicants
Applicants should focus on demonstrating the potential impact of their project on the lives of individuals with Angelman Syndrome and clearly outline how their initiative aligns with the foundation's mission.
Financial History (7 years)
| Year | Revenue | Expenses | Assets | Surplus |
|---|---|---|---|---|
| 2023 | $353K | $514K | $711K | $-160,774 |
| 2022 | $155K | $179K | $766K | $-23,958 |
| 2021 | $364K | $47K | $772K | $317K |
| 2020 | $211K | $526K | $469K | $-314,981 |
| 2019 | $366K | $196K | $770K | $170K |
| 2018 | $191K | $426K | $598K | $-235,195 |
| 2017 | $351K | $276K | $1.9M | $75K |
Community Evidence
External EvidenceIdentity
- GS ID
- AU-ABN-33141728038
- ABN
- 33141728038
- Website
- cureangelman.org.au
- Financial Year
- 2023
Focus Areas
Board & Leadership (4)
- director
- director
- director
- other
Financials
- Revenue
- $353K
- Assets
- $711K
Method
- Match Confidence
- registry
- Cross-references
- 2 datasets
- Match Key
- ABN
- Relationships
- 9
Matched by Australian Business Number (ABN) — high confidence. This entity was found across multiple government datasets using the same ABN.
Data Sources
JusticeHub
External LinkThis entity is also tracked in JusticeHub with 0 interventions and 0 evidence records.
External ecosystem profile linked from GrantScope for additional context. JusticeHub content is maintained separately.
View on JusticeHubLocation Intelligence
This entity is in a postcode ranked in the most disadvantaged 30% nationally (SEIFA Index of Relative Socio-economic Disadvantage, ABS 2021 Census).
Disability Market Context
NDIS LayerThis organisation shows disability-related delivery signals. The strategic question is whether it sits inside a resilient market, a thin market, or a captured market where large providers take most of the money and local alternatives are scarce.